WELTRUZA™ DOSING1

Start or transition your appropriate patients with a single, monthly subcutaneous injection.

WELTRUZA™ is a [new] once-monthly subcutaneous long-acting injectable formulation of olanzapine.1

Dosing conversion chart

Chart showing WELTRUZA once-monthly doses (318 mg/0.9 mL; 425 mg/1.2 mL; 531 mg/1.5 mL) and their comparable oral olanzapine daily doses (10 mg; 15 mg; 20 mg, respectively).

WELTRUZA is administered as an abdominal subcutaneous injection by a healthcare professional.

Streamlined treatment initiation with WELTRUZA

No medication icon

No loading dose or oral supplementation required

For patients who have never taken olanzapine, establish tolerability with oral or intramuscular immediate-release olanzapine prior to initiating treatment.

Clipboard icon

No post-injection monitoring required

Patients can leave after routine injection-site observation and staff can move on to the next patient.

Recycle icon

Transitioning to WELTRUZA

Give WELTRUZA on the consecutive day when transitioning from oral or intramuscular immediate-release olanzapine.

If a monthly dose is missed, administer the next injection as soon as possible and resume the monthly schedule.

Reference: 1. WELTRUZA™ (olanzapine) extended-release injectable suspension Current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc.

​

Are you a healthcare professional?

The information on WELTRUZAhcp.com is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?